Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2024 Nov 7:15:1476215.
doi: 10.3389/fimmu.2024.1476215. eCollection 2024.

Commentary: Sodium levels and immunotherapy efficacy in mRCC patients with bone metastases: sub analysis of Meet-Uro 15 study

Mehmet Fatih Ozbay  1
Affiliations
Comment

Commentary: Sodium levels and immunotherapy efficacy in mRCC patients with bone metastases: sub analysis of Meet-Uro 15 study

Mehmet Fatih Ozbay. Front Immunol. .
No abstract available

Keywords: bone metastases; immunotherapy; prognostic factors; renal cell carcinoma; scoring systems; serum sodium levels.

PubMed Disclaimer

Conflict of interest statement

The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Comment on

  • Sodium levels and immunotherapy efficacy in mRCC patients with bone metastases: sub analysis of Meet-Uro 15 study.
    Catalano M, Rebuzzi SE, Maruzzo M, De Giorgi U, Buti S, Galli L, Fornarini G, Zucali PA, Claps M, Chiellino S, Zampiva I, Pipitone S, Ricotta R, Sorarù M, Mollica V, Tudini M, Fratino L, Prati V, Caffo O, Atzori F, Morelli F, Prati G, Nolè F, Vignani F, Cavo A, Di Napoli M, Malgeri A, Naglieri E, Signori A, Banna GL, Rescigno P, Cerbone L, Antonuzzo L, Roviello G. Catalano M, et al. Front Immunol. 2024 Jul 5;15:1361010. doi: 10.3389/fimmu.2024.1361010. eCollection 2024. Front Immunol. 2024. PMID: 39034992 Free PMC article.

References

    1. Catalano M, Rebuzzi SE, Maruzzo M, De Giorgi U, Buti S, Galli L, et al. . Sodium levels and immunotherapy efficacy in mRCC patients with bone metastases: Sub analysis of Meet-URO 15 study. Front Immunol. (2024) https:1361010. doi: 10.3389/fimmu.2024.1361010 - DOI - PMC - PubMed
    1. Mocellin S, Wang E, Marincola F. Cytokines and immune response in the tumor microenvironment. Immunotherapy. (2001) 24:392–407. doi: 10.1097/00002371-200109000-00002 - DOI - PubMed
    1. Mezquita L, Auclin E, Ferrara R, Charrier M, Caramella C, Remon J, et al. . Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer. JAMA Oncol. (2018) 4:351–7. doi: 10.1001/jamaoncol.2017.4771 - DOI - PMC - PubMed
    1. Penttilä P, Bono P, Peltola K, Donskov F. Hyponatremia associates with poor outcome in metastatic renal cell carcinoma patients treated with everolimus: prognostic impact. Acta Oncologica. (2018) 57:1580–5. doi: 10.1080/0284186x.2018.1477256 - DOI - PubMed
    1. Ucà G, Mariani L, Vullo SL, Galli G, Berardi R, Nicola MD, et al. . Weighing the prognostic role of hyponatremia in hospitalized patients with metastatic solid tumors: the HYPNOSIS study. Sci Rep. (2019) 9:1–10. doi: 10.1038/s41598-019-49601-3 - DOI - PMC - PubMed

LinkOut - more resources